{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:24:59Z","timestamp":1774956299481,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Deferasirox adverse effects include the following: gastrointestinal disturbance, mild elevations in serum creatinine levels and intermittent proteinuria; these events are dose-dependent and reversible with drug discontinuation, but this solution can lead to an inadequate iron chelation. For these reasons, interindividual variability of drug plasma concentration could help the clinical management of deferasirox dosage. We sought to describe deferasirox plasma exposure in a cohort of 60 adult patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A fully validated chromatographic method was used to quantify deferasirox concentration in plasma collected from \u03b2-thalassaemia adult patients. Samples obtained before and after 2, 4, 6 and 24 h drug administration were evaluated. Associations between variables were tested using the Pearson test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Concerning pharmacokinetic parameters, a higher interindividual variability was shown. A positive correlation was found between deferasirox area under the concentration curve over 24 h and serum creatinine (r = 0.314; P = 0.018) and between area and drug dose (r = 0.311; P = 0.016). Moreover, a negative correlation resulted among area under the concentration curve over 24 h and serum ferritin (r = \u22120.291; P = 0.026) and among drug half-life and its dose (r = \u22120.319; P = 0.013).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment decision based on the individual characteristics could strongly contribute to minimize toxicity and increase efficacy of deferasirox therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12638","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T09:23:07Z","timestamp":1474968187000},"page":"1417-1421","source":"Crossref","is-referenced-by-count":10,"title":["Deferasirox pharmacokinetic and toxicity correlation in \u03b2-thalassaemia major treatment"],"prefix":"10.1093","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-0011","authenticated-orcid":false,"given":"Sarah","family":"Allegra","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin , Orbassano (TO),","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pirro","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin , Orbassano (TO),","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Massano","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin , Orbassano (TO),","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, S. Luigi Gonzaga Hospital, University of Turin , Orbassano (TO),","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,11,1]]},"reference":[{"key":"2024103012542411700_jphp12638-cit-0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"2024103012542411700_jphp12638-cit-0002","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"Beta-thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"N Engl J Med"},{"key":"2024103012542411700_jphp12638-cit-0003","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1124\/dmd.109.030833","article-title":"Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state","volume":"38","author":"Waldmeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2024103012542411700_jphp12638-cit-0004","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1124\/dmd.108.022962","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats","volume":"36","author":"Bruin","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2024103012542411700_jphp12638-cit-0005","volume-title":"Exjade (Deferasirox) Tablets for Oral Suspension [Prescribing Information]","author":"Novartis Pharmaceuticals","year":"2006"},{"key":"2024103012542411700_jphp12638-cit-0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/17512433.1.2.231","article-title":"Once-daily oral deferasirox for the treatment of transfusional iron overload","volume":"1","author":"Galanello","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024103012542411700_jphp12638-cit-0007","first-page":"565","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2024103012542411700_jphp12638-cit-0008","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2024103012542411700_jphp12638-cit-0009","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MOH.0000000000000031","article-title":"Iron chelation: an update","volume":"21","author":"Sheth","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"2024103012542411700_jphp12638-cit-0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years\u2019 follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"2024103012542411700_jphp12638-cit-0011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jbmr.522","article-title":"A case of hypophosphatemic osteomalacia secondary to deferasirox therapy","volume":"27","author":"Milat","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2024103012542411700_jphp12638-cit-0012","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"2024103012542411700_jphp12638-cit-0013","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2024103012542411700_jphp12638-cit-0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2012.02.047","article-title":"A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients","volume":"893\u2013894","author":"De Francia","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"2024103012542411700_jphp12638-cit-0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/mutage\/gev081","article-title":"Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans","volume":"31","author":"Sahota","year":"2016","journal-title":"Mutagenesis"},{"key":"2024103012542411700_jphp12638-cit-0016","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"key":"2024103012542411700_jphp12638-cit-0017","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"2024103012542411700_jphp12638-cit-0018","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.clinthera.2015.05.506","article-title":"Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV system and pharmacokinetics of deferasirox in patients with beta-thalassemia major: once-daily versus twice-daily administration","volume":"37","author":"Lu","year":"2015","journal-title":"Clin Ther"},{"key":"2024103012542411700_jphp12638-cit-0019","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/ejh.12419","article-title":"Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?","volume":"94","author":"Mattioli","year":"2014","journal-title":"Eur J Haematol"},{"issue":"6","key":"2024103012542411700_jphp12638-cit-0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2217\/pgs-2015-0001","article-title":"Role of pharmacogenetics on deferasirox AUC and efficacy","volume":"17","author":"Cusato","year":"2016","journal-title":"Pharmacogenomics"},{"key":"2024103012542411700_jphp12638-cit-0021","doi-asserted-by":"crossref","first-page":"e64114","DOI":"10.1371\/journal.pone.0064114","article-title":"Pharmacogenetic study of deferasirox, an iron chelating agent","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"2024103012542411700_jphp12638-cit-0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.2830420116","article-title":"Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major","volume":"42","author":"Brittenham","year":"1993","journal-title":"Am J Hematol"},{"key":"2024103012542411700_jphp12638-cit-0023","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000243801","article-title":"Deferasirox (Exjade) for the treatment of iron overload","volume":"122","author":"Cappellini","year":"2009","journal-title":"Acta Haematol"},{"key":"2024103012542411700_jphp12638-cit-0024","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3324\/haematol.2009.014696","article-title":"Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias","volume":"95","author":"Cappellini","year":"2010","journal-title":"Haematologica"},{"key":"2024103012542411700_jphp12638-cit-0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/0971-5851.113407","article-title":"Deferasirox in Indian children with thalassemia major: 3 years experience","volume":"34","author":"Dhamija","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2024103012542411700_jphp12638-cit-0026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0609.2007.00985.x","article-title":"Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study","volume":"80","author":"Porter","year":"2008","journal-title":"Eur J Haematol"},{"key":"2024103012542411700_jphp12638-cit-0027","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.2012.01769.x","article-title":"Observational study comparing long-term safety and efficacy of deferasirox with desferrioxamine therapy in chelation-naive children with transfusional iron overload","volume":"88","author":"Aydinok","year":"2012","journal-title":"Eur J Haematol"},{"key":"2024103012542411700_jphp12638-cit-0028","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrneph.2014.121","article-title":"Deferasirox nephrotoxicity-the knowns and unknowns","volume":"10","author":"Diaz-Garcia","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2024103012542411700_jphp12638-cit-0029","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcmd.2010.01.001","article-title":"Cystatin C levels in patients with beta-thalassemia during deferasirox treatment","volume":"44","author":"Papassotiriou","year":"2010","journal-title":"Blood Cells Mol Dis"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12638","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/11\/1417\/60229909\/jphp12638.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/68\/11\/1417\/60229909\/jphp12638.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:20:37Z","timestamp":1730312437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/68\/11\/1417\/6128215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12638","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,11]]},"published":{"date-parts":[[2016,11,1]]}}}